Back to Journals » Neuropsychiatric Disease and Treatment » Volume 4 » Issue 6

An update on the toxicity of Aβ in Alzheimer’s disease

Authors Götz J, Ittner LM, Schonrock N, Cappai R

Published 5 December 2008 Volume 2008:4(6) Pages 1033—1042


Review by Single-blind

Peer reviewer comments 9

Jürgen Götz1, Lars M Ittner1, Nicole Schonrock1, Roberto Cappai2

1Alzheimer’s and Parkinson’s Disease Laboratory, Brain and Mind Research Institute, University of Sydney, NSW, Australia; 2Department of Pathology, The University of Melbourne, Victoria, Australia

Abstract: Alzheimer’s disease is characterized histopathologically by deposition of insoluble forms of the peptide Aβ and the protein tau in brain. Aβ is the principal component of amyloid plaques and tau of neurofibrillary tangles. Familial cases of AD are associated with causal mutations in the gene encoding the amyloid precursor protein, APP, from which the amyloidogenic Aβ peptide is derived, and this supports a role for Aβ in disease. Aβ can promote tau pathology and at the same time its toxicity is also tau-dependent. Aβ can adopt different conformations including soluble oligomers and insoluble fibrillar species present in plaques. We discuss which of these conformations exert toxicity, highlight molecular pathways involved and discuss what has been learned by applying functional genomics.

Keywords: amyloid, mitochondria, oligomer, proteomic, tau, transgenic

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]